ISSN: 2475-7640

Journal of Clinical and Experimental Transplantation
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Per Lindnér

Transplant Institute, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.

Biography

He is affiliated to Transplant Institute, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. He is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals. 
 
Publications

A 1-year Comparison of Generic Tacrolimus (Tacni�?®) and Prograf�?® in Renal Transplant Patients: A Retrospective Matched Group Analysis

Introduction: The 1-year-outcome of adult patients treated with Tacni® or Prograf® following de novo renal transplantation, including patient survival, graft loss, Biopsy Proven Acute Rejection (BPAR) and serious adverse events were compared. 186 patients who underwent their first renal transplantation between 2011 and 2014 were included in... Read More»

Cecilia Lindnér and Per Lindnér

Research Article: J Clin Exp Transplant 2017

DOI: 10.4172/2475-7640.1000113

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Relevant Topics
Top